Your session is about to expire
← Back to Search
CG0070 for Bladder Cancer (BOND-003 Trial)
BOND-003 Trial Summary
This trial will test the effectiveness of CG0070, given through the bladder, in patients with NMIBC that has not responded to BCG treatment.
BOND-003 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBOND-003 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.BOND-003 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have completed the recommended BCG therapy.My organs are working well.I can take care of myself and am up and about more than half of my waking hours.My bladder cancer is high-risk and hasn't responded to BCG therapy.You currently have an autoimmune disease that is not under control.I haven't had any cancer treatment or been in a trial for new treatments in the last 4 weeks.I have a weakened immune system due to long-term steroid use, HIV, or an organ transplant.I do not have any serious or active heart problems.I have been treated with adenovirus-based cancer therapy before.I have a known cancer in my upper urinary tract or prostate.My bladder cancer has spread beyond the bladder wall.I cannot undergo or refuse to have major bladder surgery.
- Group 1: Single Arm
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many patients are involved in this clinical trial?
"A total of 110 patients are needed to fill the quotas for this clinical trial. Eligible individuals can choose to participate at sites such as Chesapeake Urology in Severna Park, Maryland and Moffit Cancer Center in Tampa, Florida."
Are patients currently able to sign up for this trial?
"The clinical trial is currently active and looking for 110 patients from 25 different sites. The first posting was on 10/27/2020, with the most recent edit occurring on 10/13/2022."
Has CG0070 undergone the FDA's process of drug approval?
"CG0070 has undergone multiple rounds of testing, so it is estimated to be a safe medication with a score of 3."
In how many different medical clinics is this research study being conducted today?
"At the moment, this study is being conducted in 25 different locations. They are situated in Severna Park, Tampa, Spokane and 22 other places. If you decide to participate in this trial, choose the site that is closest to your home to limit travel required."
Are there other similar clinical trials to this one?
"CG0070 is being trialed in 38 cities, across 5 nations. The first tests occurred in 2020 and were completed successfully; Phase 1 of the drug approval process was cleared. So far, 1 trial has been conducted since then."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
What site did they apply to?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger